An FDA advisory board has narrowly voted to decrease regulation on several controversial peptides that have gained significant traction online. These substances, including BPC-157, TB-500, and KPV, have lacked rigorous human clinical trials, yet the committee’s decision opens a path for specialized pharmacies to produce them for prescription use.
While peptides are naturally occurring proteins in the human body, the unregulated versions have become highly sought after within wellness circles and among social media influencers. This trend has spiked alongside the popularity of GLP-1 weight loss medications. Although the FDA is not obligated to adopt the panel’s guidance, the agency frequently aligns with such recommendations. Health Secretary Robert F. Kennedy has expressed personal support for the substances, previously indicating an interest in rolling back limitations imposed during the Biden administration.
Concerns persist regarding the safety and efficacy of these compounds. Critics note that substances like BPC-157, often marketed for tissue repair and gut health, remain prohibited in professional sports by the World Anti-Doping Agency due to insufficient human safety data. Panel members who opposed the motion cited the absence of quality control and clinical evidence, while supporters prioritized concepts of medical freedom. The committee is expected to continue its review of several other peptides in the coming days.
